• English
    • norsk
  • English 
    • English
    • norsk
  • Login
View Item 
  •   All institutions
  • Folkehelseinstituttet
  • Publikasjoner fra Kunnskapssenteret 2004 - 2015
  • Rapporter og andre publikasjoner fra Kunnskapssenteret
  • View Item
  •   All institutions
  • Folkehelseinstituttet
  • Publikasjoner fra Kunnskapssenteret 2004 - 2015
  • Rapporter og andre publikasjoner fra Kunnskapssenteret
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Kostnader og leveårsgevinster ved medikamentell primærforebygging av hjertekarsykdom

Wisløff, Torbjørn; Norheim, Ole Frithjof; Halvorsen, Sigrun; Selmer, Randi M; Kristiansen, Ivar Sønbø
Peer reviewed, Research report
Thumbnail
View/Open
Report, systematic review (770.8Kb)
Permanent link
http://hdl.handle.net/11250/2378420
Issue date
2008-12
Share
Metadata
Show full item record
Collections
  • Rapporter og andre publikasjoner fra Kunnskapssenteret [620]
Original version
Rapport fra Kunnskapssenteret 34/2008  
Abstract
BACKGROUND

Cardiovascular disease (CVD) has for decades been the most common cause of death in Norway and most other Western countries. Several groups of drugs have shown in clinical trials to prevent CVD. In this report, we have evaluated the cost-effectiveness of these drugs.

METHODS

Based on a model of the progression of CVD from healthy to death, we explored which drugs that might be cost-effective. Analyses were conducted both compared to no treatment and between different drugs. Analyses were conducted on different risk levels and in different age groups for both men and women. We also performed probabilistic sensitivity analyses. Our analyses were accompanied by a systematic review of other economic evaluations of preventive strategies against CVD.

RESULTS

Calcium channel blockers, thiazides, beta blockers, aspirin and statins were all cost-effective compared to no treatment for all groups of men and women in age groups between 40 and 69. The life year gains for each of the drugs varied between 3 and 17 months. Calcium channel blockers and thiazides were the most cost-effective combination of two antihypertensive drugs. In the base case analyses, the combination of calcium channel blockers, thiazides and ACE-inhibitors was the most cost-effective combination of three drugs. The sensitivity analyses indicate considerable uncertainty related to the question of which was the most cost-effective of the antihypertensive drugs. Whether treatment was cost-effective compared to no treatment was concerned with less uncertainty. Our systematic review of other economic evaluations showed considerable discrepancies between analyses of prevention strategies against CVD.

DISCUSSION

The results of this study indicate that statins, several antihypertensives and aspirin are cost-effective in all analysed groups between 40 and 69 years old. It is worthwhile noting, however, that the model is built on numerous assumptions, and this introduces considerable uncertainty with respect to optimal choice of therapies.
Publisher
Norwegian Knowledge Centre for the Health Services
Series
Rapport fra Kunnskapssenteret
34/2008

Contact Us

Search NORA
Powered by DSpace software

Service from BIBSYS
 

 

Browse this CollectionIssue DateAuthorsTitlesSubjectsDocument TypesJournalsBrowse all ArchivesArchives & CollectionsIssue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

Google Analytics StatisticsView Usage Statistics

Contact Us

Search NORA
Powered by DSpace software

Service from BIBSYS